| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad2ebb2cc64e295f079d595ac4e1c87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9228cab7cb2a462bfd176c024503317c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1216d0a09b0d6399113eb595e2ee06ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84699776c8d588f1008b1bdd5a6a936d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74fa604fcf3db33119ef72ece0b74999
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aea96214c85f8536ebefb321c5e35cd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_612254dbc956db0c2bc128de30d1f885 |
| publicationDate |
2007-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2627025-A1 |
| titleOfInvention |
Compositions and methods for inhibiting expression of huntingtin gene |
| abstract |
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell. |
| priorityDate |
2005-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |